Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA

Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA ...
Yahoo Finance

Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)

SHANGHAI, May 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the supplemental application ...
FierceBiotech

FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from S

FDA Approves Amgen's XGEVA (TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors --First Bone Targeted Therapy for Cancer Patients to Be ...
Healthline

Xgeva and Cost: What You Need to Know

Xgeva (denosumab) is a prescription drug used to treat certain bone conditions and prevent bone complications in people with cancer. Xgeva’s cost may depend on factors such as your dosage and whether ...
FiercePharma

First Bone Targeted Therapy for Cancer Patients to Be Approved in Nearly a Decade

THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Drug Store News

FDA approves Henlius and Organon’s Prolia, Xgeva biosimilars

Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos (denosumab-nxxp) injection 60 mg/ml and Bilprevda (denosumab-nxxp) injection 120 mg/1.7 ...
Healio

Delays between denosumab injections may worsen BMD response

Please provide your email address to receive an email when new articles are posted on . Lyu and colleagues analyzed electronic medical records data from 151 adults aged at least 45 years identified as ...
Medscape

Denosumab Linked to Lower Fracture Rate in Postmenopausal Women With Osteoporosis

August 11, 2009 — Denosumab injections are associated with lower fracture rate in postmenopausal women with osteoporosis, according to the results of an international, randomized, double-blind, ...
FierceBiotech

XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer

THOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA ...
FiercePharma

FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from S

Approval Based on Largest Clinical Program Ever Conducted in Patients with Bone Metastases THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) today announced ...
Insurancenewsnet.com

FDA Approves Amgen’s XGEVA™ (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors

"Today's approval of XGEVA illustrates what is possible when scientific innovation, commitment and investment come together to advance medicine," said Kevin Sharer, chairman and chief executive ...